Examination about the influence that DPP-4 inhibitor gives for a left ventricle function in acute myocardial infarction

Examination about the influence that DPP-4 inhibitor gives for a left ventricle function in acute myocardial infarction - Examination about the influence that DPP-4 inhibitor gives for a left ventricle function in acute myocardial infarction

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000014539

Enrollment

Registered

2014-07-11

Start date

2014-06-13

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute myocardial infarction, type2 diabetes mellitus

Interventions

In alogliptin group,patients will be administered alogliptin 6.25, 12.5, 25mg/day in nine-months after the percutaneous coronary intervention. In conventional treatment group, patients wil be adminis

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) The patient that percutaneous coronary angioplasty was performed for acute myocardial infarction 2) The patient who is tested for diabetes (when during the hypoglycemic drug dosage more than 6% of HbA1c international standard levels in the case of less than 9%, the non-dosage more than 6% less than 10%) 3) The patient that a document agreement by the free will of a patient was provided after enough understanding after having received enough explanation on participating of the final examination 4) Age is a patient 80 years or younger 20 years old or older at the agreement acquisition

Exclusion criteria

Exclusion criteria: 1) Severe renal disease or dialysis patient 2) Insulin-dependent patient (CPR index <0.8) 3) Patient of type I diabetes mellitus 4) The patient who uses DPP-4 inhibitor, GLP-1 preparation in either from three months ago before hospitalization to the hospitalization direct front 5) Patient having a serious liver disease 6) Patient with the possibility of the pregnancy or the pregnancy, the patient whom I am nursing 7) Patient having a side effect for DPP-4 inhibitor, antiplatelet and the anticoagulant 8) The patient who develops lower limbs confinement-related arteriosclerosis having severe lower limbs ischemia 9) Patient having heart failure of NYHAIV 10) In addition, the patient who judged an examination responsibility (allotment) doctor to be inappropriate as a subject

Design outcomes

Primary

Measure	Time frame
the change of the left ventricle function in the echocardiography	—

Countries

Japan

Contacts

Public ContactToshihiro Shoji

Chiba University Hospital Center for Cardiovascular Interventions

t-shoji@umin.ac.jp043-222-7171

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026